Earnings call transcript: Chemed Misses Q2 2025 Estimates, Shares Drop

Chemed Corporation’s second-quarter 2025 earnings fell short of expectations, with earnings per share (EPS) at $4.27, missing the forecast of $5.39. Revenue also came in below expectations at $618.8 million compared to a projected $650.6 million. Following these results, Chemed’s stock price dropped 8.8% in after-hours trading, closing at $430.20, down from a last close of $464.69. According to InvestingPro analysis, the company appears undervalued despite the earnings miss, with management actively buying back shares to support shareholder value.

Key Takeaways

• Chemed’s Q2 2025 EPS and revenue missed analyst expectations.
• Stock fell 8.8% in after-hours trading following the earnings announcement.
• Full-year EPS guidance was revised downward to $22.00-$22.30 from $24.95-$25.45.
• VITAS net revenue increased by 5.8% year-over-year.
• Roto Rooter’s adjusted EBITDA declined by 18.7% year-over-year.

Company Performance

Chemed Corporation reported mixed performance across its business units in Q2 2025. VITAS, the company’s hospice care division, saw a 5.8% increase in net revenue year-over-year, while Roto Rooter faced challenges with a significant 18.7% decline in adjusted EBITDA. The company is navigating competitive pressures in the hospice market and changes in digital advertising affecting its plumbing and drain cleaning services.

Financial Highlights

• Revenue: $618.8 million, down from the forecast of $650.6 million.
• EPS: $4.27, below the forecast of $5.39.
• VITAS net revenue: $396.2 million, up 5.8% YoY.
• Roto Rooter residential revenue: $156.4 million, up 0.9% YoY.
• Roto Rooter commercial revenue: $53.2 million, up 4.4% YoY.

Earnings vs. Forecast

Chemed’s Q2 2025 results missed analyst expectations, with an EPS surprise of -20.78% and a revenue surprise of -4.89%. This marks a significant deviation from the company’s historical trend, where it often met or exceeded forecasts. The magnitude of this miss is notable compared to previous quarters.

Market Reaction

Following the earnings release, Chemed’s stock price dropped 8.8%, reflecting investor disappointment. The stock fell to $430.20, moving closer to its 52-week low of $410. This decline contrasts with broader market trends, where many healthcare stocks have remained stable. The company maintains a moderate beta of 0.49, indicating lower volatility compared to the broader market, and has maintained dividend payments for 55 consecutive years, demonstrating long-term stability despite short-term fluctuations.

Outlook & Guidance

Chemed revised its full-year 2025 EPS guidance downward to $22.00-$22.30 from the previous $24.95-$25.45. The company anticipates improved performance in the latter half of the year, with VITAS revenue expected to increase by 7.5%-8.5% and Roto Rooter projecting a 1.25%-1.75% revenue increase. InvestingPro data shows the company maintains a strong financial health score of 3.05 out of 5, with robust cash flows sufficient to cover interest payments and a conservative debt-to-equity ratio of 0.12.

For detailed analysis and comprehensive insights into Chemed’s financial health, valuation, and growth prospects, access the full Pro Research Report, available exclusively to InvestingPro subscribers.

Executive Commentary

CEO Kevin McNamara highlighted the company’s strategic focus on acquisitions and managing Medicare cap issues, stating, "Our view is, we’re not holding our breath waiting for that number. The bigger it is, the better upside for us." CFO Mike Witzman added, "We would love to make acquisitions that are at the right valuation and in the right location."

Risks and Challenges

• Competitive pressures in the hospice market, particularly in Florida.
• Digital advertising changes impacting lead generation for Roto Rooter.
• Demographic shifts due to COVID-19 affecting patient mix.
• Increased competition from private equity-backed service providers.

Q&A

During the earnings call, analysts questioned Chemed’s strategies for managing Medicare cap issues and the challenges in Florida hospice admissions. There was also a focus on the company’s efforts to address insurance and claims cost increases and its digital marketing and lead generation strategies.

Full transcript - Chemed Corp (CHE) Q2 2025:

Conference Operator: Hello, and welcome to Chemed Corporation’s Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers’ presentation, there will be a question and answer session. I would now like to turn the conference over to Holly Schmidt. You may begin.

Holly Schmidt, Unspecified Corporate Role, Chemed Corporation: Good morning. Our conference call this morning will review the financial results for the 2025 ended 06/30/2025. Before we begin, let me remind you that the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 apply to this conference call. During the course of this call, the company will make various remarks concerning management’s expectations, predictions, plans and prospects that constitute forward looking statements. Actual results may differ materially from those projected by these forward looking statements as a result of a variety of factors, including those identified in the company’s news release of July 29 and in various other filings with the SEC.

You are cautioned that any forward looking statements reflect management’s current view only and that the company undertakes no obligation to revise or update such statements in the future. In addition, management may also discuss non GAAP operating performance results during today’s call, including earnings before interest, taxes, depreciation and amortization or EBITDA and adjusted EBITDA. A reconciliation of these non GAAP results is provided in the company’s press release dated July 29, which is available on the company’s website at chemed.com. I would now like to introduce our speakers for today, Kevin McNamara, President and Chief Executive Officer of Chemed Corporation and Mike Witzman, Chief Financial Officer of Chemed. I will now turn the call over to Kevin McNamara.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: Thank you, Holly. Good morning. Welcome to Chemed Corporation’s second quarter twenty twenty five conference call. I will begin with highlights for the quarter, then Mike will follow-up with additional details. I will then open the call for questions.

While the performance of both operating units did not meet our expectations in the 2025, we remain confident in the overall fundamentals, growth potential and strategic direction of both businesses. Admissions at DITAS during the quarter totaled 17,545, which equates to a 1.2% improvement from the same period of 2024. However, it is important to remember that over six hundred patients transferred into VITAS in the 2024 as a result of our April 2024 acquisition of Covenant Health. Excluding those transfers, admissions increased four point nine percent in the 2025. Our average daily census or ADC expanded 22,318, an increase of 6.1% when compared to the prior year quarter.

In the quarter, hospital directed admissions increased 9.1%, home based patient admissions declined 6.2%, nursing home admissions declined 2.9% and assisted living facilities admissions declined 1.4% when compared to the prior year period. We currently estimate that the consolidated Florida program will end the 2025 Medicare cap year with a $19,000,000 billing limitation. As was discussed in our June 27 press release, we were on track to mitigate the Florida Medicare billing limitation risk as of the end of the 2025. Admissions in Florida were weaker than anticipated in April and May. Accordingly, our Medicare cap projection was revised.

June and July admissions in Florida are within our expected range, but will not be enough to offset the overall billing limitation for the 2025 cap year. Management does not expect a significant level of Medicare cap billing limitation in our Florida program for the 2026 cap year. There are a number of initiatives underway that contribute to that expectation, including continued efforts on admitting short stay patients mainly through higher hospital admissions, quick ramp up of the CON startup locations in Marion and Pinellas Counties and other cap management strategies. The current projection for the 2026 cap year assumes that the rate differential that occurred for the 2025 cap year does not recur. The detailed rate information related to the reimbursement increase in Florida for the 2026 cap year will become available during the third quarter.

We intend to update our assumptions regarding rates and overall outlook for the 2026 Medicare cap year in Florida in the third quarter earnings release. Now let’s turn to Roto Rooter. Roto Rooter revenue increased 06% in the 2025 compared to the same period of 2024, falling short of our internal expectations. Branch revenue in particular was softer than anticipated with less than a 1% growth compared to the prior year. We continue to execute on the strategies implemented in 2024 that resulted in improved 2024 and the 2025 revenue trends.

Despite these efforts, April and May were particularly weak. Other large consumer facing companies have discussed the chilling effect that the Liberation Day tariff announcement had on consumer confidence and consumer spending in April and May. We believe that Roto Rooter suffered from that issue as well. June and July residential revenue has rebounded to a level that is much closer to our internal expectations. Total leads were down 7.2% in the 2025 compared with the same period of 2024.

This is a slight improvement compared to the trend we saw in the 2025. While the 2025 resulted in disappointing operating results, we remain optimistic about the overall prospects for both businesses. VITAS is in the process of adjusting their patient mix in Florida to ensure Medicare cap issues do not persist past 2025. This will cause some disruption in VITAS’ operating metrics, but positions them to return to a consistent higher growth rate for the long term. Roto remains the most recognized brand in the plumbing and drain cleaning industry.

We remain confident that the competitive advantages enjoyed by Roto Rooter will return its financial performance to a steadier growth trajectory. With that, I would like to turn the teleconference over to Mike.

Mike Witzman, Chief Financial Officer, Chemed Corporation: Thank you, Kevin. VITAS net revenue was $396,200,000 in the 2025, which is an increase of 5.8% when compared to the prior year period. This revenue increase is comprised primarily of a 6.1% increase in days of care and a geographically weighted average Medicare reimbursement rate increase of approximately 4.2%. The acuity mix shift negatively impacted revenue growth 71 basis points in the quarter when compared to the prior year revenue and level of care mix. The combination of Medicare Cap and other contra revenue changes negatively impacted revenue growth by approximately three seventy nine basis points.

The $16,400,000 Medicare cap billing limitation accrued in the 2025 is comprised of three components. First, a catch up entry of $9,500,000 was required to recognize the Medicare cap billing limitation in Florida related to the first six months of the 2025 Medicare cap year, which includes our 2024 and 2025. Second, 4,800,000.0 was recorded related to the Medicare cap billing limitation for the current 2025 related to our Florida combined program. Third, 2,100,000.0 was recognized for the current 2025 related to all other VITAS programs, mainly in California. The amount recognized for all other VITAS programs is in line with the historical run rate for these programs and our original projections for 2025.

Average revenue per patient per day in the 2025 was $207.03 which is three fifty basis points above the prior year period. During the quarter, high acuity days of care were 2.5% of total days of care, a decline of 15 basis points when compared to the prior year quarter. Average length of stay in the quarter was one hundred and thirty seven point one days. This compares to one hundred point six days in the 2024. It is important to remember that length of stay statistics are calculated based on discharged patients, not active patients.

This increase in average length of stay between quarters represents the effect of the patients admitted during our community access initiative, which was designed to identify appropriate patients earlier in their disease trajectory being discharged. Our median length of stay was twenty days in the 2025 compared to eighteen days in the same period of 2024. Adjusted EBITDA excluding Medicare Cap totaled 66,800,000 in the quarter, which is essentially flat with the 2024. Adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 16.2%, which is 163 basis points below the prior year period. The lower EBITDA margin in the quarter reflects the impact of admitting more short stay patients.

While this is the right thing to do to mitigate Medicare cap billing limitations, it has the effect of slowing revenue growth and reducing overall margin. VITAS management is currently reviewing expenses at all level of the organization to reduce costs wherever possible to help offset the lower EBITDA margin.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: Now let’s turn to Roto Rooter.

Mike Witzman, Chief Financial Officer, Chemed Corporation: Roto Rooter branch residential revenue in the quarter totaled $156,400,000 an increase of 09% from the prior year period. The residential revenue increase was driven by 16.9% increase in water restoration, offset by declines in drain cleaning, plumbing and excavation revenue. Roto Rooter branch commercial revenue in the quarter totaled $53,200,000 an increase of 4.4% from the prior year. The commercial revenue increase was driven by a 24.4% increase in excavation and an 11.7% increase in water restoration, offset by slight declines in plumbing and drain cleaning revenue. Revenue from our independent contractors declined 4.4% in the 2025 as compared to the same period of 2024.

Our independent contractors are generally smaller operations in middle market cities. In most instances, they do not have the capability to perform the add on business that is currently the primary driver of revenue growth at Roto Rooter branches. Adjusted EBITDA at Roto Rooter in the 2025 totaled $48,600,000 a decrease of 18.7% compared to the prior year quarter. The adjusted EBITDA margin in the quarter was 21.8%. The second quarter adjusted EBITDA margin represents a five seventeen basis point decline from the 2024.

The EBITDA and EBITDA margin decline was the result of a number of factors. Based on the improved revenue results seen in late twenty twenty four and early twenty twenty five, Roto Rooter began to selectively increase its productive workforce in certain high performing branches. With the sudden weakness in residential revenues seen in April and May, margins suffered from inefficiencies within the labor force. Technicians were sitting idle more than expected. This has a few effects in addition to the impact of inefficient labor use.

First, when a technician knows they may only have one or two opportunities for commission on a daily basis, they are more likely to provide discounts to secure the paying job. Second, Roto Rooter routes jobs to its highest performing technicians first. The highest performing technicians generally have higher commission rates. As a result, commissions as a percent of total revenue were higher than they have historically run. These issues should moderate as revenue rebounds in the third quarter.

Higher casualty and workers’ compensation costs negatively impacted margins by approximately two twenty basis points due mainly to actuarial estimates assuming significantly increasing costs of settling claims. Finally, as discussed in prior quarters, our cost per click for Internet marketing leads has continued to decline. However, a much greater percentage of our leads are currently coming from paid searches as compared to unpaid searches. Paid searches in the 2025 represent over 50% of all leads during the quarter. Paid searches have historically represented closer to 40% of all leads.

This has the effect of increasing costs as a percentage of revenue for our Internet marketing program. Roto Rooter management is also reviewing expenses at all levels of the organization to reduce costs wherever possible to help improve EBITDA margins going forward. Now let’s turn to the revised guidance for the remainder of 2025. VITAS full year 2025 revenue prior to Medicare cap is estimated to increase 7.5% to 8.5% when compared to 2024. Full year adjusted EBITDA margin prior to Medicare Cap is estimated to be 18.2% to 18.7%.

We are currently estimating $28,200,000 in Medicare cap billing limitations in calendar 2025. This is comprised of $19,000,000 related to the Florida combined program and $9,200,000 for all other VITAS programs. There’s no Medicare cap billing limitation in the fourth quarter included in the guidance related to the Florida combined program. This expectation assumes that the rate differential that occurred for the 2025 cap year does not recur in 2026. The detailed rate information related to the reimbursement increase in Florida for 2026 will become available during the third quarter.

We intend to update our assumptions regarding rates and the overall outlook for the 2026 Medicare cap in Florida in the third quarter earnings release. Roto Rooter is forecasted to have a 1.25% to 1.75% revenue increase in 2025 compared to 2024. Roadrunner’s adjusted EBITDA margin for 2025 is expected to be 23.5% to 24.5%. Based on the above, full year 2025 earnings per diluted share, excluding noncash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, is estimated to be in the range of $22 to $22.3 This guidance assumes an effective tax rate of 25.3% and a diluted share count of 14,700,000.0 shares. Chemed’s previously issued 2025 guidance range was $24.95 to $25.45 Chemed’s 2024 reported adjusted earnings per diluted share was $23.13 I will now turn this call back over to Kevin.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: Thank you, Mike. I will now open this teleconference to questions.

Conference Operator: Thank Our first question comes from the line of Brian Tanquilut with Jefferies. Your line is open.

Brian Tanquilut, Analyst, Jefferies: Hey, good morning, guys. Maybe my first question, as I think about your comments on the cap, right, it sounds like we shouldn’t see any impact or carryover of that after Q3. So if you can walk us through the levers you’re pulling to ensure that that happens? And then maybe how you’re thinking about the carryover impact of that in 2026 on margins and the growth rate in VITAS revenues? Thanks.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: Mike, why don’t you start with some of the technical aspects?

Mike Witzman, Chief Financial Officer, Chemed Corporation: Sure. So from a leverage standpoint, we’re still emphasizing hospital admissions, long short stay patients over long stay patients. That’s I think job number one in the levers we’re pulling. I think the other thing to keep in mind is the community access program that we ran in 2022, 2023 and some part of 2024 has created a bubble of long stay patients. And those patients will, just by definition of what we do will attrite over time.

So that bubble is going to moderate as just with the passage of time as well. So I think shorter stay patients, I think the moderation of the bubble we essentially created with the Community Access Program will certainly help over time. As far as EBITDA margins, think probably and we haven’t put pen to paper, I’m speculating a little bit, but they’re going to be below, say, what we were in 2024, which is a little over 19%. So I’m guessing and again, we haven’t really put pen to paper, but I would suggest maybe 17.5 to 18.5% is probably a pretty good range for 26%. But again, we’re coming up with those numbers as we speak.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: I just like to reiterate some of the things Mike said that with regard to why it was that we have a cap problem this year. I mean, it started with the fact that the national rate for hospice went up approximately a little over 2% last year. That’s what the cap limitation cap percentage goes up to that number. Okay. So that the differential or 3%, I said 2%, 2% delta, we got 5% in Florida.

That 2% delta is about $22,000,000 In other words, we started the year with the fact that the same the rate of reimbursement we were currently getting then was going to be $22,000,000 higher than the cap limitation that we were going to face in the 2025 cap year. We started the last year, 2024, with about a cushion of about $15,000,000 a little over $15,000,000 So we said, we have to make some changes. And it turns out that we were on power to make those changes. Two terrible months with regard to admissions for whatever reason occurred in April and May. That was enough to knock us off the trend that we were on.

And again, given the fact that we were starting with approximately $22,000,000 hole to get out of, that explains why 2025 is so unusual. And the other point that I was going to make with regard to this bubble of employee of patients that we are going through, the bubble is getting smaller at this point. But I mean, I think, and this is going into something very subjective. But during the pandemic, we saw a change in the type of we’re talking about super elderly patients. A lot of those super elderly patients, with COVID perished.

Okay. The ones that came out the other end were a little bit hardier. Okay. And, you know, tended to have for us a very long length of stay. Our average length of stay went up substantially, particularly in Florida.

Those conditions are abating. So I mean those are two significant levers. But the other thing is not to be discounted is something that, VITAS is spending night and day working on is getting a good running start on the new CON properties for our programs. And again, I think that that’s should that almost alone is enough to carry the day, but be that as it may. Yes, we are very confident that on a run rate basis, we are not looking at any we are projecting a surplus, actually, let’s put it that way.

I would also say that we have always been attuned to cap in Florida, but we have never had a cap in Florida. So I mean, yes, the organization starting at the Chemed level is got to has changed its orientation and its attention levels to this issue and we’re confident we will keep it under control. I mean, other words, internally we say, it’s twenty nineteen going to zero, not 2019 going to 40. And we’re pretty confident on that.

Brian Tanquilut, Analyst, Jefferies: That makes sense. Maybe Kevin, just to follow-up on that comment you made about the COVID impact. I mean, that you think what’s driving the relative underperformance or kind of like this trend below average on admissions? I mean, point nine, pretty good number, but still below trend. Just curious what your thoughts are.

I mean, that just the flow through of hospital admissions being soft as we look at the HCAs and tenants of the world putting up lower admissions?

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: Well, I think it’s possible, but I think the biggest issue in that is remember, all of Florida, basically all of Florida averaged this 5% increase for this plan year. That put pressure on hospices everywhere in Florida to avoid a cap, okay? Some of the dynamics for attracting particularly short stay patients, changed. So here it is, the answer to question is, why do we why is it 4.9 instead of 6.9 as far as increase? You might say, well, a little bit harder fight on the short stay patients and again, don’t have the community access orientation.

We are not pushing to we could admit a lot more patients and have a lot more revenue. But the number one thing we’re trying to avoid is providing service for free and not getting any reimbursement for it. I

Mike Witzman, Chief Financial Officer, Chemed Corporation: think the proof in the pudding is that as Kevin made in his prepared remarks, hospital admissions in the quarter were up 9% over 9%. The thing that brings that down is that we are admitting fewer patients from all the long stay pre admission locations like ALFs. And that’s intentional for the Medicare cap. So in total, in aggregate, you’re right, the 4.9% is a little bit less than the admissions we’ve had in the past. But there’s some intentionality to that because the hospital admissions are the ones we’re really focused on and we have to take in fewer admissions from those long stay things to right size the patient mix in our portfolio in Florida.

Brian Tanquilut, Analyst, Jefferies: Got it. Makes a lot of sense. Thank you so much. Appreciate it.

Conference Operator: Thank you. Please standby for our next question. Our next question comes from the line of Ben Hendrix with RBC Capital Markets.

Ben Hendrix, Analyst, RBC Capital Markets: Great. Thank you very much. Appreciate the commentary around those post COVID demographic factors that point to a more stable cap environment next year. But I want to talk a little bit about the assumption you made for 4Q this year and into next about the spread between the wage adjusted or wage indexed rates and the cap and your assumption that that doesn’t persist. Can you talk a little bit about kind of how you’re thinking about that ahead of the final rate and kind of what’s informing your view that that might not persist?

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: Well, here. Let me start by saying, it’s a good thing if it’s higher. Okay?

Mike Witzman, Chief Financial Officer, Chemed Corporation: Mhmm.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: As far as we’re concerned, we want it to be as high as possible. Okay. We will manage the business as though it was the same as the national average. In other words, if it comes in at five and I mean, the national average comes in at 2.1 and it comes at 4.1 That would be a good thing.

Okay. We would all we’re saying that probably the first month or the first quarter, the first numbers you’ll see, we’ll probably assume that there’ll be cap in Florida equal to that difference. But we will manage the business as though we were just getting it a 2.1% increase. In other words, we have it in the sense of reserve, okay. We would reserve anything over that national average and to the extent the admissions then in fact came in, okay, they would all fall to the bottom line.

Mean, was it would but we wouldn’t get to the position we’re in this year, which is being dependent on a continuation of a positive trend for instance. I mean, so it’s a good thing, if it’s higher and to be answer to your question, I think it will be a little bit higher, okay. Just because you look at the factors that we look at that are informative on a prediction of rate suggests that Florida is higher than national average. So, but we will it will be a good thing if it’s higher, but we will manage differently this year than last year. Does that make sense?

Ben Hendrix, Analyst, RBC Capital Markets: Absolutely. That’s very helpful. I appreciate that color. The Roto Rooter side, I think you noticed or mentioned in recent quarters that there were some local management issues at some of the locations that had driven some weakness. I was just wondering if there’s any linkage between efforts you’ve made or initiatives you have at the local management level and some of the recovery you’ve seen in June and July.

Mike Witzman, Chief Financial Officer, Chemed Corporation: I don’t think I think we’re pretty much past the management issues that we’ve talked about in the past. I think a lot of those were caused by people, particularly private equities poaching some of our management, not only general managers, but also the next level down where we have water restoration managers. I think that’s pretty much abated. I do think that in general, if you look at our management team in the field, at the corporate level, but at the field, it’s probably the tenure is a lot less than it would have been say pre pandemic. But I don’t think I think we’re past that now.

We’re there’s always going to be we have 51 branches, all with general managers, all with excavation managers. There’s always going to be a subset of those that are going be on some sort of performance improvement kind of plan. But I think we’re more in a normal cycle as it relates to managers. So I don’t think that’s a huge factor.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: No, I would say, if I was to summarize just to think of remedy in the hope to answer your question. If I saw two issues currently at River, they’d be and they’re not small. The small one is that Mike what Mike mentioned is, we had a new insurance program for basically general casualty last year. I mean, it was it also covered workers’ comp and whatnot. But workers’ comp costs tend to go higher as revenue goes down, employees are more likely to take time off for injuries, that type of thing.

And that was a little bit higher than it’s usually a credit for us, because we are pretty conservative in our accounting for that. So it’s usually a credit when they did the and on the casualty side, we had it came as a surprise because, you look at the number of car accidents and the severity of car accidents, they were reduced, they were lower than the expectation. So you might say, when we expected the outside firm to analyze our exposure, given the fact that there were some differences in our ultimate coverage for those assets. We didn’t expect to get credit. It came out to a big negative, was half of our decline of the margin in Road Roored.

So do we expect that to reoccur? No. Okay. I mean, we’re continuing to work on the safety and our actual results with regard to number of accidents and severity is getting better. So I think that but that’s an issue that wrecked the second quarter in many respects for Roto Rooter.

Their sales were aside from the fact that they also had a bad April and May, no question about it. They are there. But I would put all the other issues, what other what’s the problem at Roto Rooter? Why is it underperforming? It’s not management.

It’s not the labor force. The labor force has good close rates. We have good retention. I mean, it’s our as Mike said, the outflow of managers to private equity firms, if anything is reversing. I mean, they’re realizing trees don’t grow to heaven and they’re coming back or attempting to come back, some of the managers.

But the biggest issue is the phone is not ringing like did in the past. And one answer for that and that is that most currently, and this is changing, we’re in the process of some groundbreaking changes with that AI and whatnot. But I mean, the phone is not ringing as much. The potential customers go, they go to the Internet, they go to Google. If you were to type in Roto Rooter Plumbing in Google, before you even see the word Roto Rooter, there would be probably four other advertisements for rival plumbing.

I mean, is just Google does an excellent job monetizing that monopoly position. It’s changing. We’re making adjustments. Mike made a reference that to the fact that we used to get 60% basically of our output as well. We used to get 40% of our calls from paid search.

Now it’s 50%. And the reason that is because the free ones where we used to appear on maps on Google entries. We don’t appear anymore. They don’t they’re saying if we can get money for making them pay for advertisers, we’ll make sure they don’t show up in the free areas. We deal with it.

It’s a bit of adjustment for us. I think we ultimately will win that battle. We’re doing better. I think at this point every month, but it all relates to what’s the problem with rotor? The phone isn’t ringing as much as we’d like it to.

Plain and simply, we’ve

Mike Witzman, Chief Financial Officer, Chemed Corporation: got the

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: workforce. We’ve our development of water restoration and the continued refinement of our excavation business. I mean, we’re as much of an excavation and water restoration businesses we are plumbing and drain cleaning at some point. I mean, it’s one business feeds the other, but I mean, a lot of our services are those ancillary services. But we have no worry with regard to the long term persistence of success at Roto Rooter.

There’s a problem right now, no question about it. We have to say that we’ve really had some tough issues at Roto Rooter, but it’s not nearly as many on the horizon. Mike, anything what do you what’s your reaction to that?

Mike Witzman, Chief Financial Officer, Chemed Corporation: Yes, I would say, there’s no doubt as we’ve talked about in the past that the private equity competition is hurting us, particularly on the drain cleaning and the plumbing side. Those the number of jobs we do on in those two segments are continuing to decline slightly. We would love to see those increase. But we’re doing everything we can to combat that. And one of the things you see in the results specifically is, as Kevin mentioned, we are doing a much better job at identifying and converting add on sale opportunities.

So we’ve really supported the revenue at Roto Rooter with water restoration and excavation, which a lot of our private equity competitors do not do. And so we’re never going to be in a place where we offer $77 or $88 drain cleaning. That’s just we view that as a race to the bottom and we’re not going to

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: engage in It’s loss leader. They’re doing that for air conditioning business really is why they’re offering that.

Mike Witzman, Chief Financial Officer, Chemed Corporation: But we’re doing everything we can then to combat that, get around that. We’ve talked a lot about the app. We’ve talked about the service agreements that we’ve started selling. And then like I said, we’re our conversion rate is higher now than it’s ever been. In the second quarter, we converted almost 50% of our leads to paying jobs, which is significantly higher than the historical average.

So I think we’re doing a great job when the calls come in. We would like to have more calls, but I think, you know, we’re from an operating standpoint, I think we’re doing a really good job at Road Order making sure that every opportunity is converted to a paint job.

Ben Hendrix, Analyst, RBC Capital Markets: I appreciate that color guys. Last thing for me, just if you could comment on the tax rate favorability you saw in the second quarter. I just want to see if that’s a timing issue or what was behind that. Looks like about 120 basis points sequential decline in effective tax rate. Just that’s

Joanna Gajuk, Analyst, Bank of America: it for me. Thank you.

Mike Witzman, Chief Financial Officer, Chemed Corporation: It’s a bit of an accounting thing, but we get a when people exercise stock options, the company gets essentially a larger tax deduction when the stock option with what they realized compared to what we’ve recorded as the expense. And it’s, it’s just a function of how the accounting works. Obviously, with where our stock price is, we haven’t had too many stock option exercises in the quarter. And so that really drives the change in the rate. When we get a credit in our expense, we have a lot of exercises that drives down the rate and we didn’t have as many exercises in the second quarter and that’s really the big driver.

Conference Operator: Thank you. Please stand by for our next question. Our next question comes from the line of Joanna Gajuk with Bank of America. Your line is open.

Joanna Gajuk, Analyst, Bank of America: Hey, good morning. Thanks so much for taking the question. So I guess first on ZDAP, the comment around the weaker admissions, especially the short stay in Florida. Why I guess that came at that time versus earlier, if you’re saying that everyone was chasing, so to speak, these shorter stay patients. So like, why did it show up kind of later versus say, you know, when the cough situation started already in October ’24?

And then what gives you confidence in being able to get, you know, this higher mix of short stay patients going forward?

Mike Witzman, Chief Financial Officer, Chemed Corporation: Joanne, I think our confidence in the higher things going forward is really that we’ve seen a trend April and May were pretty bad. Before that, I think we were on track and June and July seem to be back on track. I can’t tell you exactly why April and May weren’t that strong. What I can tell you is when we model out the current operating statistics that we have for June and July, we are pretty confident in the 19,000,000 number for 2025 and we are also pretty confident excluding the impact of the rate issue that 2026 will not have a cap problem.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: Let’s say this. We like admits, number one. We like all admits. We want the mix to be right. How do you get a lot of admits?

Well, you have a good reputation, you keep doing what we have been doing. We could get I am picking a number, we could probably have 5% higher admits right now, if there was no Medicare cap limitation just by snapping our fingers. I mean, it’s more than doable. How do you get the right mix is really your question, Joanna. And the answer is, well, it’s by what we’ve historically said, pulling the right levers and it’s but it’s emphasis.

It’s where your salespeople are calling. It’s how fast you respond to a lead where somebody has expressed interest in having a meeting or discussion, you make sure that with regard to the hospital referral, you make sure you are there within an hour. You just it’s that type of emphasis which could put this over the top. And just so you know what we are talking about, we are talking about small changes, are talking about small improvements affecting the results by 1% or 2%, which is more than what we are talking about as far as the issues we are facing. I will just say that one of the things that the point I made to the point is, type of things we’ve done in the past when we wanted to emphasize more short state admissions were a little less they were a little more unavailing just because other people were doing the same thing.

They were following our lead. And so we just had to refine our efforts. And as Mike suggested, the results of those refined efforts are suggested to be more than adequate. And we’ll continue those, and we’ll continue to refine them.

Joanna Gajuk, Analyst, Bank of America: Alright. And then the other piece, right, when you were talking about your confidence in not having the comp issue, right, is the the new counties that you’re entering in Florida. So can you talk about the ramp up there? And is there a way to think, like, how much offsets could come from from that growth in Florida?

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: Well, let’s put it this way. We think it’s tough. I mean, because we’re new in one and it’s been a big success. Pinellas County is one that we got most recently. It’s big.

I mean, I’ll just give you an order of magnitude. Mike, what do you say there’s 8,800 admits?

Mike Witzman, Chief Financial Officer, Chemed Corporation: Yes, 8,600 admits in 2024.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: And if you multiply that number by $36,000 you see that that’s maybe $350,000,000 for coverage for Medicare cap billing. I mean, it’s the opportunities there. Now with regard to, let’s say, for Dallas County, we just have awarded it. There’s elements of finalization and dealing with appeals that we have to do. In our projections where I said we’re projecting no cap in the fourth quarter or anything significant cap next year, that does not depend on Pinellas County.

Mike Witzman, Chief Financial Officer, Chemed Corporation: None of our projections include any projection for Pinellas County.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: Now if you ask me, will we be operating and thriving in Pinellas County in the next government plan year, I have no doubt we will. But that’s not the basis. Our basis is just making slight improvements in the state as a whole. But those are we mentioned those regularly for the next it begs the question, well, what about the next year? The answer is Pinellas County for one should be booming by that, let’s put it that way.

Mike Witzman, Chief Financial Officer, Chemed Corporation: Yes, mean, ultimately the new CONs will buy us a little bit of extra time to right size the patient mix, which is what we’re doing and which is what we’ve talked about for the 2025 and all of 2026.

Joanna Gajuk, Analyst, Bank of America: Right. And I guess you alluded to the idea of like you don’t know for sure in the Florida rate update yet, right, because we didn’t see the details yet. But it sounds like you based on some other data points where you’re thinking that it’s likely that it’s going to be some of that issue repeat. But sounds like you think it’s smaller, right? So I guess you’re saying that despite the fact that you think that there’s consideration that there could be the gap delta that there’s enough of these other things you could do in terms of the mix and then potentially, you know, that’s not even a considerate the new counties, right?

Mike Witzman, Chief Financial Officer, Chemed Corporation: So, right, so our current models would show that we have somewhere in the we are projecting 15,000,000 to $20,000,000 cushion next year in Florida, but that does not include any potential credit we could get in Pinellas, but it also doesn’t include any of the rate differential. I think the we’ve done some analysis on what we think the hospital wages look like in Florida. We think it is going to be above the national average. Having said that, what we saw in 2025 was a wider spread than we’ve ever seen in the twenty years we’ve owned VITAS.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: But keep on going. I don’t

Mike Witzman, Chief Financial Officer, Chemed Corporation: know that we would expect that to continue, but even if it does, we will manage to that number either way.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: We want it to be as high as possible. Okay. We’d like it to we’d like a 3% delta. I mean, give us but we would reserve it. In other words, all we’re saying in that case, if they get if there was a 2% delta, we got 4% in Florida and 2% nationwide that Medicare cap limitation went up two percent.

The first month what we would do in our results until proven otherwise, we would take we would then say we have Florida Medicare billing limitation until we we take the money we’ve got from the government, we’ve set it aside knowing we’re probably going to have to give it back unless we unless the admits came in the door, the additional admits. So it’s a heads, you win tails, you don’t lose situation if the cap is high if the increase in reimbursement is higher in Florida national average, it’s good.

Mike Witzman, Chief Financial Officer, Chemed Corporation: Ultimately, what we’re trying to say, Joanna, is that our current operating model and the current trends that we’re on will not result in any cap in 2026. There’s an unknown with the rate differential. We’ll deal with that when that comes. We’ll let you know what it is when it comes. But our current operating model will suggest that we will not have any cap.

If we try to put in to the model some sort of rate differential, would be it would purely be a swag. And we don’t think that, that makes sense to do when we’re trying to essentially portray that the 2019 is going to zero, not 19 to 50, as Kevin mentioned.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: And I guess what you’ll see next year, and I’m putting myself in your position. You say, okay, what should we do for estimates and expectations? Just for Florida, you should assume that the Medicare cap limitation will go up in a sense the national average. Anything above that, ignore, because it will be like California for us. In other words, we know right now California is very profitable and that we make all our estimates, we say, okay, there is going to be about 8,000,000 of cap in the state.

If we got an increase, if it was 2%, if it was 2% higher than national average, we’d say, well, technically we’re going to come in exactly where we thought, but we will have a Medicare cap reporting of in Florida in that case, all things being equal, whether say $20,000,000 okay. We would know that, we would state that on the day that we had the information from the Florida reimbursement, what it was. And I, we will ignore that internally. We suggest analysts kind of ignore that and just say, they may have to give $20,000,000 back to the state of Florida, but there’s a good chance they’ll do better than that and have to give less or none back to the federal government. I mean, so we’ll see how it comes, but it’s not a big issue to us.

Our view is, we’re not holding our breath waiting for that number. The bigger it is, the better upside for us, but we are going to try and make it next year for everyone, people whose job it is to predict, and analyze the results of the company, a non entity and not something that does not affect the ultimate task that you’re doing. Does that does that make sense, Mike? I have a Yeah. I mean, it’s kind of a tough one because we it sounds like a bogeyman, Medicare Cap, but that wouldn’t surprise me at all if it’s different.

Mean, are the odds it’s going be exactly the

Joanna Gajuk, Analyst, Bank of America: same? Right. All right. Thanks for that. And maybe just quickly on the other business, just to clarify.

So you called out this higher insurance, I guess, accrual in the quarter, but then you said something about you don’t think it’s going to persist, but you did raise your margin for the segment, for the broader segment by 200 basis points. But do you assume that the issues you’re saying could persist for the rest of the year?

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: Well, here’s what the point. First of all, is a catch up element to it. I mean, it is more than the expense we took is more than what we took in the affected in a quarter is more than one quarter’s result impact, number one. And number two, the point that if Roto Rooter could continue to do a good job reducing the number of accidents and the severity of them, it’s got nowhere to go but down. Now, let me start by saying that we had a new based on the insurance market, there were we have a new policy, different deductible, different elements.

There are some adjustments we have to make as far as managing it. But no, we don’t expect big surprises in the on the road expense side of that regard. And so when I say don’t persist, there is no magic bullet other than it was a lot to take in, in one quarter, number one. And number two, we going to do a better job managing and predicting it. But ultimately, the answer to your question, Joanna, is just that, our emphasis on safety and reducing those type of expenses, doing a much better job monitoring the insurance adjusters who are settling these claims that type of things that’s where we’re going to see the improvement.

So if you combine it with good experience and much more emphasis on what happens after the accident occurs, there’s a lot of confidence on our part that level of expense you saw and the level of deterioration in the margin that you saw in the second quarter will not persist.

Mike Witzman, Chief Financial Officer, Chemed Corporation: And as Kevin mentioned, in the almost $5,000,000 extra hit we took, at least there’s some of that that is out of period. But just so you know, when you’re doing your model, Joanna, we did include an increase in those costs of $4,000,000 in total for the second half of the year. We didn’t want to be caught short again, not at least considering those costs in the guidance we put out.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: But the improvements I’m talking about will take some time to put in.

Mike Witzman, Chief Financial Officer, Chemed Corporation: So in the guidance that we’ve put out, Roto Rooter has baked in $4,000,000 so $2,000,000 each quarter of additional expense for this issue. Could it be better than that? We think it could be, but it’s hard to say, but we

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: don’t We want to get short of won’t have a hard data until the next report by the outside auditing firm.

Joanna Gajuk, Analyst, Bank of America: Alright. That’s helpful. And if I may, just last one on, capital deployment, where is the cash flow pretty good? I know that, yes, there’s, you know, issues in one business and the other. Does those things change your view of things?

Because I wanna say, you know, you did the hospice acquisition, and at that time, you kinda were alluding that, you know, there could be more like that. So can you kind of refresh your, commentary around that? Like is there any change in threats, the thought process around maybe there’s some consolidation that has to be done? Thank you.

Mike Witzman, Chief Financial Officer, Chemed Corporation: There’s no change in strategy, Joanna. We would love to make acquisitions that are at the right valuation and on the VITAS side in the right location. We continue to monitor and have those conversations. It’s a bit of a long lead time because we’re contacting people, we’re contacting organizations, essentially cold calling them in some instances to see their appetite for making such a transaction. And so there’s a bit of a long lead time for those, but there’s no change in the direction of what we would like to do.

Having said that, regardless of the cash or what’s on no debt on the balance sheet, we’re not going to just buy things to grow. They had to be at the right valuation, they had to be at the right place, in the right location. And I would also tell you, there’s no change in the idea that because of our strength of our balance sheet, significant share buybacks and acquisitions are not mutually exclusive. We can do both. And that’s why we’ve kept the balance sheet the way it is.

So I would expect some movement in the third quarter probably on a share buyback perspective. But otherwise, there’s no change to our overall strategy.

Conference Operator: Great. Thank you. Thank you. I’m showing no further questions in the queue. I would now like to turn the call back over to Kevin for closing remarks.

Kevin McNamara, President and Chief Executive Officer, Chemed Corporation: Well, I just want to thank everyone for their kind attention. And we’ve got a tough quarter for our operating units and I think we’re well on the way to improving the outlook and we’ll see in our next report three months from now. Thank you.

Conference Operator: Ladies and gentlemen, that concludes today’s conference call. Thank you for your participation. You may now disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.